Anti-Human PD-L1 Reference Antibody (GR1405, RUO) (HV974296)

Name: Anti-Human PD-L1 Reference Antibody (GR1405, RUO)
Brand: abinScience
SKU: HV974296
Price: 370 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV974296
Descripción	Anti-Human CD274/PD-L1/B7-H1 (GR1405) (HV974296) is a research-grade recombinant antibody targeting CD1. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FCM, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG
ID de clon	GR1405
Objetivo	B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q9NZQ7
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	GR1405
Fondo	Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi). 1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443 2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410 3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417 4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419 5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298 6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077 7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201
Nota	For research use only. Not suitable for clinical or therapeutic use.